This event is being co-organized with the American Association for the Study of Liver Diseases (AASLD) and is useful for hepatologists, virologists, translational and clinical researchers, health professionals and young trainees.
Topics to be covered include; epidemiology, pathogenesis and virology, HCV assessment and treatment, special patient populations, cClinical and translational research. The recent and rapid advances in the treatment of hepatitis C have completely changed the scenario of this disease in the last months. It is not always easy to be updated in the field, due to the huge amount of data coming from a large number of published studies. Antiviral drugs that are still not approved in some countries are already classified as 'old' and current treatment regimens may be replaced by new ones by the time the meeting takes place.
The aim of the EASL-AASLD Special Conference is to summarize the information available, as well as to provide a critical review and analysis of the best available data (some unpublished data will be relevant). With this goal in mind, this meeting will give hepatologists, as well as other specialists interested in hepatitis C, the opportunity to catch up with the new advances in the field and be able to apply them in clinical practice. To reach this aim, an international panel of key experts and participants will actively interact to resolve pending issues and to highlight areas needing further analysis and investigation.
Sponsorship and exhibition opportunities are available for those interested in making a lasting impression within the global liver community.
Topics to be covered include; epidemiology, pathogenesis and virology, HCV assessment and treatment, special patient populations, cClinical and translational research. The recent and rapid advances in the treatment of hepatitis C have completely changed the scenario of this disease in the last months. It is not always easy to be updated in the field, due to the huge amount of data coming from a large number of published studies. Antiviral drugs that are still not approved in some countries are already classified as 'old' and current treatment regimens may be replaced by new ones by the time the meeting takes place.
The aim of the EASL-AASLD Special Conference is to summarize the information available, as well as to provide a critical review and analysis of the best available data (some unpublished data will be relevant). With this goal in mind, this meeting will give hepatologists, as well as other specialists interested in hepatitis C, the opportunity to catch up with the new advances in the field and be able to apply them in clinical practice. To reach this aim, an international panel of key experts and participants will actively interact to resolve pending issues and to highlight areas needing further analysis and investigation.
Sponsorship and exhibition opportunities are available for those interested in making a lasting impression within the global liver community.
